Sherrington Robin - Mar 7, 2024 Form 4 Insider Report for Xenon Pharmaceuticals Inc. (XENE)

Role
EVP, Strategy & Innovation
Signature
/s/ Nathaniel Adams, Attorney-in-fact
Stock symbol
XENE
Transactions as of
Mar 7, 2024
Transactions value $
-$314,300
Form type
4
Date filed
3/8/2024, 05:31 PM
Previous filing
Jan 2, 2024
Next filing
Mar 12, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction XENE Common Shares Options Exercise $12.2K +1.23K +14.69% $9.85 9.63K Mar 7, 2024 Direct F1
transaction XENE Common Shares Tax liability -$9.88K -215 -2.23% $45.96 9.42K Mar 7, 2024 Direct F2
transaction XENE Common Shares Options Exercise $73K +7.41K +78.66% $9.85 16.8K Mar 7, 2024 Direct F1
transaction XENE Common Shares Tax liability -$59.2K -1.29K -7.66% $45.96 15.5K Mar 7, 2024 Direct F2
transaction XENE Common Shares Sale -$47K -1.02K -6.56% $46.15 14.5K Mar 7, 2024 Direct F3
transaction XENE Common Shares Sale -$283K -6.12K -42.15% $46.30 8.4K Mar 7, 2024 Direct F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction XENE Stock Option (Right to Buy) Options Exercise $0 -1.23K -100% $0.00* 0 Mar 7, 2024 Common Shares 1.23K $9.85 Direct F1, F5
transaction XENE Stock Option (Right to Buy) Options Exercise $0 -7.41K -100% $0.00* 0 Mar 7, 2024 Common Shares 7.41K $9.85 Direct F1, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The exercise price was converted from $10.78 CAD using the closing rate of exchange of the Bank of Canada on the date of grant, after giving effect to the 1-for-4.86 reverse stock split of the Issuer's outstanding shares effected October 1, 2014 (the "Reverse Stock Split"). The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise.
F2 Represents the closing price of the Company's common shares on March 6, 2024 for purposes of net settlement calculations.
F3 The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These share were sold in multiple transactions at prices ranging from $46.15 to $46.17, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
F4 The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These share were sold in multiple transactions at prices ranging from $46.25 to $46.36, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
F5 The shares subject to this option are fully vested and exercisable.